Viracta Therapeutics January 2024 Investor Presentation

Viracta Therapeutics presents its clinical development pipeline focused on EBV-associated lymphomas and solid tumors, along with programs targeting other virus-associated malignancies. The presentation covers the NAVAL-1 trial results and the company's plans for potential new drug application filings based on preliminary findings. Led by an experienced leadership team with deep expertise in viral oncology.